drugset / Trial / NCT02546492
Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar
Phase 4
Terminated
6 enrolled
University of Maryland, Baltimore
University of Alabama at Birmingham · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label safety and feasibility trial using Acthar® in addition to the investigators center-specific standard therapy, which could include increase in maintenance immunosuppression, high dose IVIG (intravenous immunoglobulin) (2 g/Kg), and/or Rituximab, in patients with chronic antibody-mediated rejection (CAMR).
Timeline
- Start
- 2016-08
- Primary completion
- 2021-05-27
- Completion
- 2021-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acthar | Peptide | 80 iu | Subcutaneous |